If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  TOBI Maintains Lung Function Improvements In CF Patients MONTREAL, QC -- Oct. 16, 1998 -- Clinical trial data from an 18-month study on PathoGenesis Corp.’s Tobi® (tobramycin solution for inhalation) for the management of cystic fibrosis patients with Pseudomonas aeruginosa was presented at the North American Cystic Fibrosis Conference. The results showed that cystic fibrosis patients continued to maintain improved lung function above baseline values after 18 months of the chronic intermittent Tobi treatment regimen -- 28 days on drug, 28 days off drug. After 18 months, previously published literature suggests that these patients might otherwise have lost, on average, about six percent of lung function relative to baseline had they not been taking Tobi. They found that delay of Tobi therapy led to irreversible loss of lung function. Patients who were in the placebo group for six months before beginning Tobi therapy never achieved absolute lung function values comparable to those achieved by patients who were treated with Tobi throughout the 18-month study. Each ready-to-use ampule of Tobi contains 300 milligrams of tobramycin in a five millilitre solution. Tobi is aerosolised and administered using a PARI LC PLUS(TM) reusable nebulizer and a DeVilbiss Pulmo-Aide(R) compressor. It is inhaled twice daily and requires about 15 minutes per treatment. The Tobi treatment regimen consists of repeated cycles of 28 days on drug, followed by 28 days off drug. Tobi is approved for sale in the U.S., and regulatory applications are pending in other countries. Related Links: Tobi, PathoGenesis Corp.
|
